Modelling approaches for antibody decay of malaria vaccines

Modelling approaches for antibody decay of malaria vaccines

Malaria remains a primary cause of illness and mortality in sub-Saharan Africa and vaccines that interrupt or diminish transmission are key strategies to reduce this burden. Our prior work modeling the decline in antibody titers with Pfs 230/AS01e a transmission blocking vaccine (currently in Phase 2 clinical trials) has yielded interesting approaches for describing the durability of antibody titers after vaccination. In the proposed research we would apply the same hierarchical Bayesian modeling we have used for the transmission blocking vaccine and apply them to the data from the RTS,S trial. Using this model we plan to estimate probability of antibody response and decay given response. The results of the models may inform whether the dose schedules for both vaccines can be aligned in order to justify any future trials of co-administration of the vaccines to both prevent individual infection as well as prevent additional transmission of malaria.

[{ "PostingID": 19809, "Title": "GSK-104743", "Description": "A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, two candidate malaria vaccines in malaria-experienced adults living in Western Kenya." }]